Neuren Pharmaceuticals Ltd
NEU
Company Profile
Business description
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
Contact
117 Camberwell Road
Suite 1.01
Hawthorn East
MelbourneVIC3123
AUST: +61 390920480
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
37
Stocks News & Analysis
stocks
This defensive ASX listed REIT offers a 5% yield
Solid outlook underpinned by rent uplifts and development pipeline.
stocks
Chart of the Week: Anthropic’s IPO range sits below our fair value
Our fair value is above the IPO range, but outcomes could differ widely.
stocks
Taking a look at opportunities in gaming shares as the highly anticipated GTA 6 is released
Several gaming shares are trading at a discount to our fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,836.60 | 95.80 | -1.07% |
| CAC 40 | 8,189.95 | 43.12 | 0.53% |
| DAX 40 | 25,930.50 | 194.26 | 0.75% |
| Dow JONES (US) | 50,198.17 | 561.25 | -1.11% |
| FTSE 100 | 10,550.40 | 0.77 | -0.01% |
| HKSE | 22,841.62 | 453.13 | -1.95% |
| NASDAQ | 24,429.88 | 101.50 | 0.42% |
| Nikkei 225 | 59,444.21 | 419.93 | 0.71% |
| NZX 50 Index | 14,247.25 | 17.04 | -0.12% |
| S&P 500 | 7,323.63 | 16.90 | -0.23% |
| S&P/ASX 200 | 8,730.40 | 91.40 | -1.04% |
| SSE Composite Index | 3,577.62 | 10.21 | -0.28% |